Skip to main content

Table 1 The comparison of outcomes in each hACE2 Tg mouse model to SARS-CoV infection

From: COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice

  K18-hACE2 [66, 67] AC70, AC22, and AC63 [59, 68] HFH4-ACE2 [69] Mouse ACE2 promoter-driven hACE2 Tg mice [70]
Promoter Human K18 promoter CAG promoter Human HFH4 promoter Mouse ACE2 promoter
Parental mice of zygotes (C57BL/6J × SJL/J) F2 (C57BL/6J × C3H/HeJ) F1 (C3H × C57BL/6) F1 ICR
Viral strains Urbani Urbani Urbani PUMC01
TCID50aof SARS-CoV 1.6 × 104b AC70: 103
AC22: 106
AC63: 106
7 × 104c 105
Mortality (%) Line 1: 100
Line 2: 100
Line 3: 100
AC70: 100
AC22: 0
AC63: 0
100 0
Survival days (p.i.) Line 1: 2–5
Line 2: 3–4
Line 3: 5–7
AC70: 4–8
AC22: n.a.d
AC63: n.a.
5–6 n.a.
  1. aTCID50 50% tissue culture infective dose
  2. bThe viral dosage used in the study, 2.3 × 104 plaque-forming units (PFU), was converted to the estimated TCID50 by the conversion TCID50 ≈ 0.7 PFU [71].
  3. cThe viral dosage used in the study, 105 PFU, was converted to the estimated TCID50 by the conversion TCID50 ≈ 0.7 PFU [71].
  4. dNot applicable
\